Pfizer 배당금 및 환매

배당금 기준 확인 5/6

Pfizer 은(는) 현재 수익률이 7.32% 인 배당금 지급 회사입니다. 다음 지급일은 13th June, 2025 이며 배당락일은 다음과 같습니다. 9th May, 2025.

주요 정보

7.3%

배당 수익률

n/a

환매 수익률

총 주주 수익률	n/a
미래 배당 수익률	7.6%
배당금 성장	4.7%
다음 배당금 지급일	13 Jun 25
전 배당일	09 May 25
주당 배당금	n/a
지급 비율	122%

최근 배당금 및 환매 업데이트

Recent updates

Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline

May 28

Pfizer's Q1 Update May Mark A Bottom In The Stock

Apr 30

Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle

Apr 23

It Looks Like Pfizer Inc.'s (NYSE:PFE) CEO May Expect Their Salary To Be Put Under The Microscope

Apr 17

Pfizer: Tasty 7% Yield

Apr 16

R&D And Savings Programs Will Strengthen Future Outlook

Apr 08 Focus on R&D productivity in 2025 may risk misalignment with market needs, impacting future revenue if new products underperform.

Oncology Integration And Phase III Trials Will Redefine Future

Apr 07 Pfizer's oncology focus strengthens its portfolio and future revenue through Seagen integration and promising R&D pipeline developments in oncology and vaccines.

Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade)

Mar 28

Pfizer: Bulls Need To Check Out Its Graham P/E

Mar 22

Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency

Mar 20I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines

Pfizer: Undervalued Safe Haven In Risk-Off Market

Mar 11

Pfizer Remains A Good Pick For Dividend Investors

Mar 04

Market Still Lacking Some Conviction On Pfizer Inc. (NYSE:PFE)

Feb 28

Why Pfizer's Stock Price Isn't Reflecting Its True Value

Feb 19

Pfizer: 3 Key Risks That Warrant A Sell

Feb 12

Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down

Feb 04

These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively

Feb 04

Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider

Jan 28

Pfizer's (NYSE:PFE) Upcoming Dividend Will Be Larger Than Last Year's

Jan 13

Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy

Jan 13

Pfizer: One Of The Next Big AI Winners

Dec 30

Pfizer (NYSE:PFE) Is Paying Out A Larger Dividend Than Last Year

Dec 30

Pfizer: Time And Patience Ran Out (Rating Downgrade)

Dec 24

Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call

Dec 18

Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.43

Dec 16

Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns

Dec 11

Pfizer: Too Cheap To Ignore

Dec 05

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: PFE 의 주당 배당금은 지난 10 년 동안 안정적이었습니다.

배당금 증가: PFE 의 배당금 지급은 지난 10 년 동안 증가했습니다.

시장 대비 배당 수익률

Pfizer 시장 대비 배당 수익률

PFE 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (PFE)	7.3%
시장 하위 25% (US)	1.6%
시장 상위 25% (US)	4.8%
업계 평균 (Pharmaceuticals)	2.8%
애널리스트 예측 (PFE) (최대 3년)	7.6%

주목할만한 배당금: PFE 의 배당금( 7.32% )은 US 시장에서 배당금 지급자의 하위 25%( 1.56% )보다 높습니다. 1.56% ).

고배당: PFE 의 배당금( 7.32% )은 US 시장( 4.78% )

주주에 대한 수익 배당금

수익 보장: 지급 비율 ( 121.8% )이 높기 때문에 PFE 의 배당금 지급은 수익으로 잘 충당되지 않습니다.

주주에 대한 현금 배당금

현금 흐름 범위: 현재 현금 지급 비율 ( 87.2% )에서 PFE 의 배당금 지급은 현금 흐름으로 충당됩니다.

강력한 배당금 지급 기업 알아보기

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/30 12:17
장 마감 주가	2025/05/30 00:00
수익	2025/03/30
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Pfizer Inc. 54 애널리스트 중 24 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
David Toung	Argus Research Company
Kerry Holford	Berenberg
Luisa Hector	Berenberg

Pfizer 배당금 및 환매

배당금 기준 확인 5/6

주요 정보

최근 배당금 및 환매 업데이트

Fourth quarter dividend of US$0.43 announced

Pfizer Inc. Declares Second-Quarter 2025 Dividend, Payable on June 13, 2025

Upcoming dividend of US$0.43 per share

Pfizer's (NYSE:PFE) Upcoming Dividend Will Be Larger Than Last Year's

Pfizer (NYSE:PFE) Is Paying Out A Larger Dividend Than Last Year

Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.43

Recent updates

Pfizer Inc. Announces Statically Significant and Clinically Significant Results from the Phase 3 BREAKWATER Trial Evaluating BRAFTOVI®? (Encorafenib) in Combination with Cetuximab and mFOLFOX6

Case Management Conference in the Depo-Provera Legal Action Against Pfizer Inc

Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline

Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2

Pfizer's Q1 Update May Mark A Bottom In The Stock

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Pfizer Inc. Reaffirms Earnings Guidance for the Year 2025

Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naive, High-Risk Non-Muscle Invasive Bladder Cancer

Fourth quarter dividend of US$0.43 announced

Pfizer Inc. Declares Second-Quarter 2025 Dividend, Payable on June 13, 2025

Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle

It Looks Like Pfizer Inc.'s (NYSE:PFE) CEO May Expect Their Salary To Be Put Under The Microscope

ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO to Include Adults Aged 50 to 59 At Increased Risk of Disease

Pfizer: Tasty 7% Yield

Pfizer Inc. Provides Update on Oral Glp-1 Receptor Agonist Danuglipron

R&D And Savings Programs Will Strengthen Future Outlook

Oncology Integration And Phase III Trials Will Redefine Future

Entwistle & Cappucci LLP Files Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc

European Commission Approves Pfizer's RSV Vaccine ABRYSVO to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease

Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade)

Pfizer: Bulls Need To Check Out Its Graham P/E

Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency

Pfizer Inc. to Report Q1, 2025 Results on Apr 29, 2025

Pfizer Inc., Annual General Meeting, Apr 24, 2025

Arvinas, Inc. and Pfizer Inc. Announce Positive Topline Results from Phase 3 Veritac-2 Clinical Trial

Pfizer: Undervalued Safe Haven In Risk-Off Market​

Pfizer Remains A Good Pick For Dividend Investors

Market Still Lacking Some Conviction On Pfizer Inc. (NYSE:PFE)

Chairman of the Board & CEO exercised options and sold US$904k worth of stock

Insider exercised options and sold US$243k worth of stock

Why Pfizer's Stock Price Isn't Reflecting Its True Value

Pfizer’s TALZENNA in Combination with XTANDI Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer

U.S. FDA Approves Pfizer's ADCETRIS Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Pfizer: 3 Key Risks That Warrant A Sell

Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer

Pfizer Inc. Provides Earnings Guidance for the Year 2025

Full year 2024 earnings: EPS misses analyst expectations

Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down

These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively

Pfizer’s Braftovi Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 Breakwater Trial

Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider

Pfizer Inc. Announces Positive Results from the Phase 3 Breakwater Trial Evaluating Braftovi® (Encorafenib) in Combination with Cetuximab and Mfolfox6

Upcoming dividend of US$0.43 per share

Pfizer Intends to Sell Approximately 700 Million Ordinary Shares in Haleon

Pfizer's (NYSE:PFE) Upcoming Dividend Will Be Larger Than Last Year's

Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Pfizer: One Of The Next Big AI Winners

Pfizer (NYSE:PFE) Is Paying Out A Larger Dividend Than Last Year

Pfizer: Time And Patience Ran Out (Rating Downgrade)

U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

Pfizer Inc. to Report Q4, 2024 Results on Feb 04, 2025

Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call

Pfizer Inc. Provides Earnings Guidance for the Fiscal Year 2025; Reaffirms Earnings Guidance for the Year 2024

Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.43

Third quarter dividend increased to US$0.43

Pfizer Inc. Declares First-Quarter 2025 Dividend, Payable on March 7, 2025

Pfizer’s IBRANCE in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer

Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns

Arvinas and Pfizer Announces Initial Phase 1B Data from the Tactive-U Sub-Study of Vepdegestrant in Combination with Abemaciclib At 2024 San Antonio Breast Cancer Symposium

Pfizer: Too Cheap To Ignore

Pfizer Inc. Announces Executive Changes

Pfizer Reportedly Explore Sale of Hospital Drugs Unit

Pfizer, Inc. and Global Blood Therapeutics, Inc. Sued over Alleged Sickle Cell Drug Side Effects

Pfizer Inc. Revises Earnings Guidance for the Year 2024

Pfizer Inc. Announces Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

Pfizer Inc. Announces Election of Mortimer J. Buckley to Its Board of Directors

U.S. FDA Approves Pfizer Inc.’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

Pfizer Inc. Announces Positive Topline Results from the Final Prespecified Overall Survival Analysis of the TALAPRO-2 Study of TALZENNA®

Pfizer: Undervalued Safe Haven In Risk-Off Market